Does the media prefer EPRX or SRPT?

In the previous week, Sarepta Therapeutics had 2 more articles in the media than Eupraxia Pharmaceuticals. MarketBeat recorded 4 mentions for Sarepta Therapeutics and 2 mentions for Eupraxia Pharmaceuticals. Eupraxia Pharmaceuticals' average media sentiment score of 1.11 beat Sarepta Therapeutics' score of 0.67 indicating that Eupraxia Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Eupraxia Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Sarepta Therapeutics 3 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has better earnings & valuation, EPRX or KOD?

Eupraxia Pharmaceuticals is trading at a lower price-to-earnings ratio than Kodiak Sciences, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Eupraxia Pharmaceuticals N/A N/A -$38.58M -$1.02 N/A Kodiak Sciences N/A N/A -$229.97M -$4.19 N/A

Is EPRX or KOD more profitable?

Eupraxia Pharmaceuticals' return on equity of -63.97% beat Kodiak Sciences' return on equity. Company Net Margins Return on Equity Return on Assets Eupraxia Pharmaceuticals N/A -63.97% -43.32% Kodiak Sciences N/A -273.23% -85.48%

Does the media prefer EPRX or KOD?

In the previous week, Kodiak Sciences had 3 more articles in the media than Eupraxia Pharmaceuticals. MarketBeat recorded 5 mentions for Kodiak Sciences and 2 mentions for Eupraxia Pharmaceuticals. Eupraxia Pharmaceuticals' average media sentiment score of 1.11 beat Kodiak Sciences' score of 0.49 indicating that Eupraxia Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Eupraxia Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Kodiak Sciences 1 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media prefer VCEL or EPRX?

In the previous week, Vericel and Vericel both had 2 articles in the media. Eupraxia Pharmaceuticals' average media sentiment score of 1.11 beat Vericel's score of 0.96 indicating that Eupraxia Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Vericel 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Eupraxia Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor NUVB or EPRX?

In the previous week, Nuvation Bio had 11 more articles in the media than Eupraxia Pharmaceuticals. MarketBeat recorded 13 mentions for Nuvation Bio and 2 mentions for Eupraxia Pharmaceuticals. Eupraxia Pharmaceuticals' average media sentiment score of 1.11 beat Nuvation Bio's score of 0.39 indicating that Eupraxia Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Nuvation Bio 3 Very Positive mention(s) 3 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral Eupraxia Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is EPRX or GENB more profitable?

Generate Biomedicines' return on equity of 0.00% beat Eupraxia Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Eupraxia Pharmaceuticals N/A -63.97% -43.32% Generate Biomedicines N/A N/A N/A

Does the media favor EPRX or GENB?

In the previous week, Generate Biomedicines had 4 more articles in the media than Eupraxia Pharmaceuticals. MarketBeat recorded 6 mentions for Generate Biomedicines and 2 mentions for Eupraxia Pharmaceuticals. Eupraxia Pharmaceuticals' average media sentiment score of 1.11 beat Generate Biomedicines' score of 0.35 indicating that Eupraxia Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Eupraxia Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Generate Biomedicines 1 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Eupraxia Pharmaceuticals (EPRX) Competitors

$8.58 -0.06 (-0.69%)

Closing price 04:00 PM Eastern

Extended Trading

$8.65 +0.07 (+0.82%)

As of 07:46 PM Eastern

Compare

EPRX vs. SRPT, KOD, VCEL, NUVB, and GENB

Should you buy Eupraxia Pharmaceuticals stock or one of its competitors? Eupraxia Pharmaceuticals's main competitors and comparable companies include Sarepta Therapeutics (SRPT), Kodiak Sciences (KOD), Vericel (VCEL), Nuvation Bio (NUVB), and Generate Biomedicines (GENB). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Eupraxia Pharmaceuticals compare to Sarepta Therapeutics?

Eupraxia Pharmaceuticals (NASDAQ:EPRX) and Sarepta Therapeutics (NASDAQ:SRPT) are both healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, valuation, risk, institutional ownership, analyst recommendations, media sentiment, earnings and profitability.

86.7% of Sarepta Therapeutics shares are held by institutional investors. 6.9% of Sarepta Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

In the previous week, Sarepta Therapeutics had 2 more articles in the media than Eupraxia Pharmaceuticals. MarketBeat recorded 4 mentions for Sarepta Therapeutics and 2 mentions for Eupraxia Pharmaceuticals. Eupraxia Pharmaceuticals' average media sentiment score of 1.11 beat Sarepta Therapeutics' score of 0.67 indicating that Eupraxia Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Eupraxia Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Sarepta Therapeutics	3 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Eupraxia Pharmaceuticals has a beta of 1.07, indicating that its stock price is 7% more volatile than the broader market. Comparatively, Sarepta Therapeutics has a beta of 0.27, indicating that its stock price is 73% less volatile than the broader market.

Eupraxia Pharmaceuticals has a net margin of 0.00% compared to Sarepta Therapeutics' net margin of -13.48%. Sarepta Therapeutics' return on equity of -1.60% beat Eupraxia Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Eupraxia Pharmaceuticals	N/A	-63.97%	-43.32%
Sarepta Therapeutics	-13.48%	-1.60%	-0.66%

Eupraxia Pharmaceuticals has higher earnings, but lower revenue than Sarepta Therapeutics. Eupraxia Pharmaceuticals is trading at a lower price-to-earnings ratio than Sarepta Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Eupraxia Pharmaceuticals	N/A	N/A	-$38.58M	-$1.02	N/A
Sarepta Therapeutics	$2.20B	1.00	-$713.41M	-$2.90	N/A

Eupraxia Pharmaceuticals currently has a consensus target price of $18.00, indicating a potential upside of 109.79%. Sarepta Therapeutics has a consensus target price of $24.07, indicating a potential upside of 15.65%. Given Eupraxia Pharmaceuticals' stronger consensus rating and higher possible upside, equities research analysts plainly believe Eupraxia Pharmaceuticals is more favorable than Sarepta Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Eupraxia Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	2 Strong Buy rating(s)	2.89
Sarepta Therapeutics	6 Sell rating(s)	5 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.11

Summary

Eupraxia Pharmaceuticals and Sarepta Therapeutics tied by winning 8 of the 16 factors compared between the two stocks.

How does Eupraxia Pharmaceuticals compare to Kodiak Sciences?

Eupraxia Pharmaceuticals (NASDAQ:EPRX) and Kodiak Sciences (NASDAQ:KOD) are both healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their analyst recommendations, media sentiment, dividends, earnings, valuation, profitability, risk and institutional ownership.

Eupraxia Pharmaceuticals' return on equity of -63.97% beat Kodiak Sciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Eupraxia Pharmaceuticals	N/A	-63.97%	-43.32%
Kodiak Sciences	N/A	-273.23%	-85.48%

Eupraxia Pharmaceuticals is trading at a lower price-to-earnings ratio than Kodiak Sciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Eupraxia Pharmaceuticals	N/A	N/A	-$38.58M	-$1.02	N/A
Kodiak Sciences	N/A	N/A	-$229.97M	-$4.19	N/A

89.1% of Kodiak Sciences shares are owned by institutional investors. 44.4% of Kodiak Sciences shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Eupraxia Pharmaceuticals has a beta of 1.07, suggesting that its stock price is 7% more volatile than the broader market. Comparatively, Kodiak Sciences has a beta of 2.18, suggesting that its stock price is 118% more volatile than the broader market.

In the previous week, Kodiak Sciences had 3 more articles in the media than Eupraxia Pharmaceuticals. MarketBeat recorded 5 mentions for Kodiak Sciences and 2 mentions for Eupraxia Pharmaceuticals. Eupraxia Pharmaceuticals' average media sentiment score of 1.11 beat Kodiak Sciences' score of 0.49 indicating that Eupraxia Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Eupraxia Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Kodiak Sciences	1 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Eupraxia Pharmaceuticals presently has a consensus price target of $18.00, suggesting a potential upside of 109.79%. Kodiak Sciences has a consensus price target of $53.67, suggesting a potential upside of 58.78%. Given Eupraxia Pharmaceuticals' stronger consensus rating and higher possible upside, research analysts plainly believe Eupraxia Pharmaceuticals is more favorable than Kodiak Sciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Eupraxia Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	2 Strong Buy rating(s)	2.89
Kodiak Sciences	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57

Summary

Eupraxia Pharmaceuticals beats Kodiak Sciences on 8 of the 13 factors compared between the two stocks.

How does Eupraxia Pharmaceuticals compare to Vericel?

Vericel (NASDAQ:VCEL) and Eupraxia Pharmaceuticals (NASDAQ:EPRX) are both healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their risk, analyst recommendations, earnings, valuation, institutional ownership, dividends, media sentiment and profitability.

Vericel presently has a consensus price target of $58.40, indicating a potential upside of 45.20%. Eupraxia Pharmaceuticals has a consensus price target of $18.00, indicating a potential upside of 109.79%. Given Eupraxia Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe Eupraxia Pharmaceuticals is more favorable than Vericel.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Vericel	0 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.67
Eupraxia Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	2 Strong Buy rating(s)	2.89

Vericel has a net margin of 7.91% compared to Eupraxia Pharmaceuticals' net margin of 0.00%. Vericel's return on equity of 6.91% beat Eupraxia Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Vericel	7.91%	6.91%	5.02%
Eupraxia Pharmaceuticals	N/A	-63.97%	-43.32%

Vericel has higher revenue and earnings than Eupraxia Pharmaceuticals. Eupraxia Pharmaceuticals is trading at a lower price-to-earnings ratio than Vericel, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Vericel	$276.26M	7.46	$16.52M	$0.47	85.57
Eupraxia Pharmaceuticals	N/A	N/A	-$38.58M	-$1.02	N/A

Vericel has a beta of 1.04, indicating that its stock price is 4% more volatile than the broader market. Comparatively, Eupraxia Pharmaceuticals has a beta of 1.07, indicating that its stock price is 7% more volatile than the broader market.

In the previous week, Vericel and Vericel both had 2 articles in the media. Eupraxia Pharmaceuticals' average media sentiment score of 1.11 beat Vericel's score of 0.96 indicating that Eupraxia Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Vericel	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Eupraxia Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Vericel beats Eupraxia Pharmaceuticals on 7 of the 13 factors compared between the two stocks.

How does Eupraxia Pharmaceuticals compare to Nuvation Bio?

Nuvation Bio (NYSE:NUVB) and Eupraxia Pharmaceuticals (NASDAQ:EPRX) are both healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, media sentiment, profitability, analyst recommendations, valuation, risk, dividends and institutional ownership.

Eupraxia Pharmaceuticals has a net margin of 0.00% compared to Nuvation Bio's net margin of -88.18%. Nuvation Bio's return on equity of -46.59% beat Eupraxia Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Nuvation Bio	-88.18%	-46.59%	-22.01%
Eupraxia Pharmaceuticals	N/A	-63.97%	-43.32%

61.7% of Nuvation Bio shares are held by institutional investors. 30.1% of Nuvation Bio shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Nuvation Bio presently has a consensus target price of $13.00, suggesting a potential upside of 112.38%. Eupraxia Pharmaceuticals has a consensus target price of $18.00, suggesting a potential upside of 109.79%. Given Nuvation Bio's higher possible upside, equities research analysts clearly believe Nuvation Bio is more favorable than Eupraxia Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nuvation Bio	1 Sell rating(s)	2 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.69
Eupraxia Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	2 Strong Buy rating(s)	2.89

In the previous week, Nuvation Bio had 11 more articles in the media than Eupraxia Pharmaceuticals. MarketBeat recorded 13 mentions for Nuvation Bio and 2 mentions for Eupraxia Pharmaceuticals. Eupraxia Pharmaceuticals' average media sentiment score of 1.11 beat Nuvation Bio's score of 0.39 indicating that Eupraxia Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Nuvation Bio	3 Very Positive mention(s)	3 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral
Eupraxia Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Eupraxia Pharmaceuticals has lower revenue, but higher earnings than Nuvation Bio. Nuvation Bio is trading at a lower price-to-earnings ratio than Eupraxia Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nuvation Bio	$62.90M	34.17	-$204.63M	-$0.44	N/A
Eupraxia Pharmaceuticals	N/A	N/A	-$38.58M	-$1.02	N/A

Nuvation Bio has a beta of 1.52, suggesting that its share price is 52% more volatile than the broader market. Comparatively, Eupraxia Pharmaceuticals has a beta of 1.07, suggesting that its share price is 7% more volatile than the broader market.

Summary

Nuvation Bio beats Eupraxia Pharmaceuticals on 10 of the 16 factors compared between the two stocks.

How does Eupraxia Pharmaceuticals compare to Generate Biomedicines?

Eupraxia Pharmaceuticals (NASDAQ:EPRX) and Generate Biomedicines (NASDAQ:GENB) are both healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their earnings, risk, media sentiment, valuation, dividends, profitability, analyst recommendations and institutional ownership.

Eupraxia Pharmaceuticals currently has a consensus price target of $18.00, indicating a potential upside of 109.79%. Generate Biomedicines has a consensus price target of $26.40, indicating a potential upside of 51.20%. Given Eupraxia Pharmaceuticals' stronger consensus rating and higher probable upside, analysts clearly believe Eupraxia Pharmaceuticals is more favorable than Generate Biomedicines.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Eupraxia Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	2 Strong Buy rating(s)	2.89
Generate Biomedicines	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63

Eupraxia Pharmaceuticals has higher earnings, but lower revenue than Generate Biomedicines. Generate Biomedicines is trading at a lower price-to-earnings ratio than Eupraxia Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Eupraxia Pharmaceuticals	N/A	N/A	-$38.58M	-$1.02	N/A
Generate Biomedicines	$31.89M	70.27	-$203.15M	-$1.59	N/A

Generate Biomedicines' return on equity of 0.00% beat Eupraxia Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Eupraxia Pharmaceuticals	N/A	-63.97%	-43.32%
Generate Biomedicines	N/A	N/A	N/A

In the previous week, Generate Biomedicines had 4 more articles in the media than Eupraxia Pharmaceuticals. MarketBeat recorded 6 mentions for Generate Biomedicines and 2 mentions for Eupraxia Pharmaceuticals. Eupraxia Pharmaceuticals' average media sentiment score of 1.11 beat Generate Biomedicines' score of 0.35 indicating that Eupraxia Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Eupraxia Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Generate Biomedicines	1 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Eupraxia Pharmaceuticals beats Generate Biomedicines on 7 of the 12 factors compared between the two stocks.

Get Eupraxia Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding EPRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

EPRX vs. The Competition

Export

Metric	Eupraxia Pharmaceuticals	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$561.76M	$3.91B	$7.27B	$13.25B
Dividend Yield	N/A	3.64%	2.53%	13.00%
P/E Ratio	-8.41	14.43	274.29	25.85
Price / Sales	N/A	1,380.68	636.12	91.27
Price / Cash	N/A	109.50	76.31	52.02
Price / Book	6.09	15.83	10.70	6.42
Net Income	-$38.58M	-$22.82M	$3.49B	$360.08M
7 Day Performance	5.80%	1.96%	2.37%	2.35%
1 Month Performance	27.49%	-3.43%	-1.73%	-2.48%
1 Year Performance	29.02%	37.20%	17.91%	6.42%

Eupraxia Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
EPRX Eupraxia Pharmaceuticals	2.341 of 5 stars	$8.58 -0.7%	$18.00 +109.8%	+45.0%	$561.76M	N/A	N/A	49	News Coverage Positive News
SRPT Sarepta Therapeutics	3.0057 of 5 stars	$20.67 +4.6%	$25.69 +24.3%	+15.5%	$2.09B	$2.20B	N/A	835
KOD Kodiak Sciences	2.0114 of 5 stars	$32.85 +0.2%	$48.14 +46.6%	+240.2%	$2.06B	N/A	N/A	124
VCEL Vericel	3.7355 of 5 stars	$40.03 -0.4%	$58.40 +45.9%	+24.8%	$2.06B	$276.26M	85.17	398
NUVB Nuvation Bio	2.7709 of 5 stars	$6.09 +5.3%	$13.00 +113.6%	+89.4%	$2.03B	$169.90M	N/A	305	Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:EPRX) was last updated on 9/22/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Eupraxia Pharmaceuticals (EPRX) Competitors

EPRX vs. SRPT, KOD, VCEL, NUVB, and GENB

How does Eupraxia Pharmaceuticals compare to Sarepta Therapeutics?

Summary

How does Eupraxia Pharmaceuticals compare to Kodiak Sciences?

Summary

How does Eupraxia Pharmaceuticals compare to Vericel?

Summary

How does Eupraxia Pharmaceuticals compare to Nuvation Bio?

Summary

How does Eupraxia Pharmaceuticals compare to Generate Biomedicines?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

EPRX vs. The Competition

Eupraxia Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Eupraxia Pharmaceuticals (EPRX) Competitors

EPRX vs. SRPT, KOD, VCEL, NUVB, and GENB

How does Eupraxia Pharmaceuticals compare to Sarepta Therapeutics?

Do institutionals and insiders believe in EPRX or SRPT?

Does the media prefer EPRX or SRPT?

Which has more risk & volatility, EPRX or SRPT?

Is EPRX or SRPT more profitable?

Which has preferable valuation & earnings, EPRX or SRPT?

Do analysts recommend EPRX or SRPT?

Summary

How does Eupraxia Pharmaceuticals compare to Kodiak Sciences?

Is EPRX or KOD more profitable?

Which has better earnings & valuation, EPRX or KOD?

Do institutionals and insiders hold more shares of EPRX or KOD?

Which has more risk and volatility, EPRX or KOD?

Does the media prefer EPRX or KOD?

Do analysts rate EPRX or KOD?

Summary

How does Eupraxia Pharmaceuticals compare to Vericel?

Do analysts recommend VCEL or EPRX?

Is VCEL or EPRX more profitable?

Which has better valuation and earnings, VCEL or EPRX?

Which has more risk & volatility, VCEL or EPRX?

Does the media prefer VCEL or EPRX?

Summary

How does Eupraxia Pharmaceuticals compare to Nuvation Bio?

Is NUVB or EPRX more profitable?

Do insiders and institutionals hold more shares of NUVB or EPRX?

Do analysts prefer NUVB or EPRX?

Does the media favor NUVB or EPRX?

Which has better earnings and valuation, NUVB or EPRX?

Which has more risk & volatility, NUVB or EPRX?

Summary

How does Eupraxia Pharmaceuticals compare to Generate Biomedicines?

Do analysts prefer EPRX or GENB?

Which has stronger valuation and earnings, EPRX or GENB?

Is EPRX or GENB more profitable?

Does the media favor EPRX or GENB?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

EPRX vs. The Competition

Eupraxia Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools